Jolle Kirpensteijn1, Marja Kik, Erik Teske, Gerard R Rutteman. 1. Department of Clinical Sciences of Companion Animals and Pathobiology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands. j.kirpensteijn@uu.nl
Abstract
OBJECTIVE: To investigate mutations of the TP53 gene in canine osteosarcoma (OS). STUDY DESIGN: Clinical historic cohort study. ANIMALS: Client-owned dogs. METHODS: OS (n=59) were screened for mutations of the complete TP53 gene using polymerase chain reaction and the mutation was analyzed by single-strand conformational polymorphism. Clinical outcome of dogs with TP53-mutated OS were compared with dogs with OS without a mutation after complete surgical excision of the primary tumor. RESULTS: TP53 gene mutations were observed in 24 of 59 (40.7%) OS; 3 mutated OS had 2 mutations. The alterations consisted mainly of point mutations (74%). Dogs with mutated OS had a significantly shorter survival time (ST) after surgery than dogs with normal tumor TP53 gene expression (P=.03). Other significant prognosticators for ST and disease-free interval included elevated serum alkaline phosphatase (P<.01) and tumor grade (P=.01). CONCLUSION: TP53 genetic mutations are common in canine OS and may have a prognostic value. CLINICAL RELEVANCE: Mutations of the TP53 gene may influence survival and should be considered when evaluating canine OS.
OBJECTIVE: To investigate mutations of the TP53 gene in canineosteosarcoma (OS). STUDY DESIGN: Clinical historic cohort study. ANIMALS: Client-owned dogs. METHODS: OS (n=59) were screened for mutations of the complete TP53 gene using polymerase chain reaction and the mutation was analyzed by single-strand conformational polymorphism. Clinical outcome of dogs with TP53-mutated OS were compared with dogs with OS without a mutation after complete surgical excision of the primary tumor. RESULTS:TP53 gene mutations were observed in 24 of 59 (40.7%) OS; 3 mutated OS had 2 mutations. The alterations consisted mainly of point mutations (74%). Dogs with mutated OS had a significantly shorter survival time (ST) after surgery than dogs with normal tumorTP53 gene expression (P=.03). Other significant prognosticators for ST and disease-free interval included elevated serum alkaline phosphatase (P<.01) and tumor grade (P=.01). CONCLUSION:TP53 genetic mutations are common in canine OS and may have a prognostic value. CLINICAL RELEVANCE: Mutations of the TP53 gene may influence survival and should be considered when evaluating canine OS.
Authors: Arin N Graner; Justin E Hellwinkel; Alex M Lencioni; Helen J Madsen; Tessa A Harland; Paul Marchando; Ger J Nguyen; Mary Wang; Laura M Russell; Lynne T Bemis; Thomas J Anchordoquy; Michael W Graner Journal: Int J Hyperthermia Date: 2016-12-20 Impact factor: 3.914
Authors: Gayathri T Selvarajah; Floor A S Bonestroo; Jolle Kirpensteijn; Marja J L Kik; Ruurd van der Zee; Willem van Eden; Elpetra P M Timmermans-Sprang; Adri Slob; Jan A Mol Journal: Cell Stress Chaperones Date: 2013-03-06 Impact factor: 3.667
Authors: Gayathri T Selvarajah; Jolle Kirpensteijn; Monique E van Wolferen; Nagesha A S Rao; Hille Fieten; Jan A Mol Journal: Mol Cancer Date: 2009-09-07 Impact factor: 27.401
Authors: Marieke L Kuijjer; Elisabeth F P Peterse; Brendy E W M van den Akker; Inge H Briaire-de Bruijn; Massimo Serra; Leonardo A Meza-Zepeda; Ola Myklebost; A Bassim Hassan; Pancras C W Hogendoorn; Anne-Marie Cleton-Jansen Journal: BMC Cancer Date: 2013-05-20 Impact factor: 4.430